Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome
Authors:
- 1 May 1989
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 33 (5) , 736-741
Abstract
Ten patients with acquired immunodeficiency syndrome with newly diagnosed cytomegalovirus (CMV) retinitis were treated with an induction regimen of intravenous foscarnet, 60 mg/kg of body weight, administered as a 2-h infusion and repeated every 8 h for 14 days. At the end of induction, 9 of 10 patients had stabilized (no new retinal lesions and stable old lesions [7 patients]) or improved (decreased retinal opacification [2 patients]). All eight patients with CMV in urine or blood upon entry into the study had negative urine and blood cultures at the end of induction. After induction therapy, seven patients continued maintenance foscarnet therapy, 60 mg/kg as a single daily infusion, 5 days/week. In six patients, retinal lesions increased in size after 2 to 32 weeks of maintenance therapy. One was invaluable because a retinal detachment developed. Only 9 of 42 blood and urine cultures obtained during maintenance foscarnet therapy yielded CMV, compared with 7 of 14 obtained prior to the initiation of foscarnet induction therapy (P = 0.04). Foscarnet toxicity was mild and infrequent: elevation in serum creatinine by 0.5 to 1.3 mg/dl over the base line (two patients), muscle twitching (three patients), hemoglobin decrease by 1 mg/dl (two patients), nausea (two patients), absolute neutrophil count decrease by 50% (one patient), rise in serum phosphorus to greater than 5.5 mg/dl (four patients), and proteinuria (two patients). Intermittently administered intravenous foscarnet appears to be an effective, relatively nontoxic therapy for CMV retinitis. Additional studies to determine the optimal dosage for maintenance therapy are needed, as are comparative trials with ganciclovir.Keywords
This publication has 14 references indexed in Scilit:
- Ganciclovir Treatment of Life- or Sight-Threatening Cytomegalovirus Infection: Experience in 314 Immunocompromised PatientsClinical Infectious Diseases, 1988
- Randomized prospective trial of ganciclovir maintenance therapy for cytomegalovirus retinitisJournal of Medical Virology, 1988
- Treatment of Cytomegalovirus Retinitis with Trisodium Phosphonoformate Hexahydrate (Foscarnet)The Journal of Infectious Diseases, 1988
- Treatment of Cytomegalovirus Retinopathy in Patients With Acquired Immunodeficiency SyndromeArchives of Ophthalmology (1950), 1986
- Inhibition of human renal epithelial Na+/Pi cotransport by phosphonoformic acidBiochemical and Biophysical Research Communications, 1986
- Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipientsJournal of Antimicrobial Chemotherapy, 1986
- FOSCARNET FOR CYTOMEGALOVIRUS INFECTIONSThe Lancet, 1985
- INHIBITION OF HUMAN T-CELL LYMPHOTROPIC VIRUS TYPE III IN VITRO BY PHOSPHONOFORMATEThe Lancet, 1985
- Effects of the nucleoside analog 2'-nor-2'-deoxyguanosine on human cytomegalovirus replicationAntimicrobial Agents and Chemotherapy, 1984
- Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on human cytomegalovirus replication in vitroAntimicrobial Agents and Chemotherapy, 1983